Introduction
Rotator cuffs heal through a scar tissue interface following repair that makes them prone to failure. MT1-MMP is upregulated during embryogenesis in areas that develop into tendon-bone insertion sites. The purpose of this study was to determine if the application of mesenchymal stem cells (MSCs) transduced with Ad-MT1-MMP could improve regeneration of the tendon-bone insertion site in a rotator cuff repair model. Our hypothesis was that pluripotent stem cells in the presence of the developmental signal from MT1-MMP would drive the healing process towards regeneration and away from scar formation.
Methods
In this IACUC-approved study, 68 Lewis rats underwent unilateral detachment and repair of the supraspinatus. Thirty animals received MSCs in a fibrin glue carrier; 30 received Ad-MT1-MMP-transduced MSCs. Ad-MT1-MMP was constructed in our laboratory with the AdEasy kit (Stratagene). MSCs were transduced in vitro with 10 5 pfu/ cell. Prior to implantation, the tranduced MSCs were confirmed to have adequate MT1-MMP gene expression in vitro with rtPCR. Eight animals were used to confirm gene deliveries in vivo using Ad-LacZ-transduced MSCs. Fifteen animals in each group were killed at 2 and 4 weeks. At each time point, three animals were used for histology, 12 for biomechanical testing. Outcomes included semiquantitative histologic analysis to determine new cartilage formation (area of metachromasia with safranin-O) and collagen fiber organization (birefringence under polarized light with picrosirius red). Biomechanical testing was performed to determine the ultimate load-to-failure, cross-sectional area, ultimate stress at failure, and stiffness. Statistical analysis was performed with Wilcoxon rank-sum test with significance at p=0.05.
Results
Animals which received MSCs transduced with Ad-LacZ exhibited more betagalactosidase staining as compared to MSCs alone at both 2 and 4 weeks. In vitro, there was 219-fold greater MT1-MMP expression in the transduced MSCs compared to untransduced MSCs. There were no differences between the Ad-MT1-MMP and MSC groups in any outcome variable at 2 weeks. At 4 weeks, the Ad-MT1-MMP group had more new cartilage formation (p=0.05), higher ultimate load-to-failure (p=0.01), higher ultimate stress-to-failure (p=0.005), and higher stiffness values (p=0.02) as compared to the MSC group.
Discussion
Mesenchymal stem cells genetically modified to overexpress the developmental gene MT1-MMP can augment rotator cuff healing at 4 weeks by inducing more fibrocartilage formation that resulted in improved biomechanical strength. The mechanisms for these findings are not clear, but MT1-MMP may modify the extracellular matrix into a more organized insertion site. It may also make cells more sensitive to growth factors resulting in proliferation and differentiation of the pluripotent cells. Limitations of the study include the use of a small animal, acute injury model that may limit the ability to extrapolate these results to humans. Furthermore, the study was not powered for histology; therefore, differences may have been present, but our study was underpowered to detect them. In conclusion, biologic augmentation of repaired rotator cuffs with MT1-MMP transduced MSCs may reduce the incidence of retears. However, further studies are needed to determine if this remains safe and effective in larger models. Introduction/Background Dendritic cells (DCs) are the most potent of antigen presenting cells, capable of initiating and regulating a host's response to pathogens. While immature, they are efficient at phagocytosis of exogenous antigen in the periphery. In the mature state, they lose this ability but gain the capacity to present antigen on their cell surface. It is known that in order to activate a T cell, the DC must supply at least two signals: relevant antigen in the context of MHC and a second costimulatory signal, such as CD80 or CD86. Although both of them are calcineurin inhibitors, Tacrolimus (FK506), but not cyclosporine, is effective treatment for paraneoplastic autoimmune neurologic degeneration, a disease known to be dependent on DC activation of T cells to exogenously acquired antigen. Taking hints from this clinical phenomenon, we hypothesized that FK506 would block DC ability to activate T cells to exogenous antigen. The goal of this work is to analyze how treatment with the two drugs may differently affect DC maturation state, transcription profile, and function.
Materials and Methods
Immature DCs were cultured from CD14+ selected peripheral blood mononuclear cells for 6 days in IL-4 and GCSF. DCs were co-cultured with apoptotic flu infected 3T3 cells for 8 h to allow for phagocytosis. Cells were then given a maturation stimulus of TNF and PGE-2 in the presence or absence of immunomodulatory drug. Forty hours later, mature DCs were harvested and analyzed via FACS analysis, frozen and used to generate microarray transcription profiles, or co-cultured with purified syngeneic CD4 or CD8 T cells with CD40L and plated in an IFNγ elispot assay. Directly flu-infected DCs were used as a positive control; DCs co-cultured with uninfected apoptotic 3T3 cells served as a negative control. FACS data were generated on a FacsCalibur and analyzed with FloJo software. Biotinylated cRNA fragments were prepared from monocyte-derived DCs as per Affymetrix protocol, loaded onto Affymetrix U133A. Microarray data were analyzed on GeneSpring software.
Results
FK506 treatment of DCs blocked their subsequent ability to activate both CD4 and cyclosporine CD8 T-cell responses to exogenously acquired antigen in the IFNγ elispot assay, while cyclosporine had no effect. Interestingly, DC treatment with either drug failed to block T-cell responses to endogenously acquired antigen in the form of influenza infected DCs. IL12 partially rescued the FK506-mediated DC block in an antigen specific manner, implying that MHC/antigen peptide complexes are indeed present on the FK506 treated DC cell surface. Furthermore, T cells that had been co-cultured with FK506-treated DCs for 7 days remain blocked from producing IFNγ when rechallenged with a maximal stimulus. This indicates that the lack of IFNγ production by T cells cocultured with FK506-treated DCs is a result of tolerance induction rather than T-cell ignorance. FACS analysis of FK506-and cyclosporine-treated DCs does not reveal significant differences in DC maturation cell surface markers such as MHC II, CD83, or the costimulatory molecules CD80 and CD86. Therefore, the divergent immunologic outcomes cannot be explained by differences in DC maturation state. FK506 treatment does not affect DC expression of MHC/ antigen or costimulatory molecules but blocks the ability of a DC to activate T cells implying that a third as yet undefined signal is required for T cell activation. In an attempt to identify the third signal required for full DC activation, microarray transcription profiles comparing gene expression of cyclosporine-to FK506-treated DCs were generated. These arrays failed to reveal a difference that could explain the profoundly different immunological outcomes.
Discussion
In conclusion, although both FK506 and cyclosporine are calcineurin inhibitors, their effect on DC function is profoundly different. Cyclosporine has very little effect on T-cell responses to either endogenously or exogenously acquired antigen. FK506, on the other hand, severely limits the ability of a DC to activate T-cell responses to exogenously acquired antigen. No difference was seen among drug treatment groups in DC maturation state as measured by CD80, CD83, CD86, or MHC II expression. Additionally, it does not appear that FK506 treatment blocks antigen presentation of the cell surface. The fact that the FK506-treated DCs are presenting antigen (signal 1) and costimulatory molecules (signal 2) but not activating T-cell responses implies that a third, as yet unidentified signal, is required for a DC to activate T cells. The lack of difference in gene array profiles in cyclosporine-and FK506-treated DCs implies that this third signal is regulated by a mechanism under posttranscriptional control. As immune responses often need to be generated quickly, it stands to reason that RNA may be present in the cell, but translation held in check until the cell receives full activation. The discovery of a third signal required for DC activation may reveal new drug targets for treating autoimmune disease and provide a novel mechanism for generating a fully mature yet tolerogenic DC phenotype for use in DC-based vaccines.
Introduction
Failure to achieve secure tendon-to-bone healing after anterior cruciate ligament (ACL) reconstruction may be an important cause of recurrent laxity. The weakest link following reconstruction is not the graft itself but rather the fixation points until graft osteointegration occurs. Modulation of the mechanical environment may have profound effects on the cellular and molecular events at the healing tendon-bone interface. The purpose of this study was to determine how controlled axial loading after ACL reconstruction affects tendon-to-bone healing. Our hypotheses was that controlled, cyclic, axial loading after a period of immobilization may provide a more favorable mechanical environment for tendon-bone healing after ACL reconstruction than immediate axial loading or prolonged immobilization.
Materials and Methods
One hundred fifty-six male Sprague-Dawley rats (weight= 300-350 g) underwent ACL reconstruction using a flexor digitorum longus autograft. A custom-designed jig was used to drill collinear tunnels in the femur and tibia and apply an external fixator across the knee that was parallel to the ACL graft. All other ligaments and capsular constraints of the knee were sectioned to ensure that the ACL graft was loaded. The graft was pretensioned manually and secured with suspensory fixation to the surrounding periosteum at the tunnel exits. Animals were randomly assigned to (1) strict immobilization (n=36), (2) immediate (n=36), (3) at POD#4 ("early delayed loading" n=42), (4) at POD#10 ("late delayed loading" n=42) cyclic, controlled loading to achieve 2% axial strain. Daily loading was performed via a novel in vivo joint distraction device such that displacement of the femur and tibia was constrained to axial translation parallel to the graft tunnels. The joint was distracted at 0.24 mm/s until the graft reached 2% strain (defined as the relative translation of the tibia and femur scaled by the distance between tunnel exits at the time of surgery) and then returned to neutral for a total of 50 cycles. The applied strain to the graft was validated using an optical tracking system to measure graft strain after ACL reconstruction. Animals were sacrificed at 14 or 28 days postoperatively for biomechanical testing, μCT, and histomorphometric analysis. Data were statistically analyzed using a two-way ANOVA followed by post hoc Tukey test.
Results
Biomechanical Testing: Delayed initiation of cyclic axial loading at POD#10 resulted in significantly increased loadto-failure of the femur-ACL-tibia complex at 2 weeks compared to immediate loading or prolonged immobilization of the knee (9.6±3.3 versus 4.4±2.3 and 4.4±1.5 N, respectively; p=0.01; Figure 1 ). Initiation of cyclic loading at POD#4 also resulted in greater load-to-failure at 2 weeks compared to immediately loaded or immobilized specimens (7.4±3.1 versus 4.4±2.3 and 4.4±1.5 N, respectively); this difference approached but did not achieve significance (p= 0.09). At 4 weeks, the POD#4 group demonstrated significantly greater load-to-failure than all other groups (13.5±4 versus~8±4 N, respectively; p=0.01; Figure 1 ). Construct stiffness of the POD#10 group was significantly greater than all other groups at 2 weeks postoperatively (6.1±2.2 versus~3.8±1.8 N/mm, respectively; p=0.04). However, no significant differences in stiffness were observed between any groups at 4 weeks postoperatively. μCT analysis: Significantly greater new bone formation and tissue mineral content was observed in the tibial tunnels of the delayed loading groups compared to immediate loading, immobilized, and time 0 control animals at both 2 and 4 weeks postoperatively (p<0.01; Table 1 ). Regional tunnel analysis revealed similar differences for new bone formation at the intra-articular aperture and mid-tunnel (p<0.01), but no differences at the tunnel exit. Histology: Qualitative analysis demonstrated less fibrovascular scar tissue at the tendon-bone interface in the delayed loading groups compared to immediate loading or immobilized groups at 2 and 4 weeks. There were significantly less ED1+ inflammatory macrophages at the interface in both POD#4 and POD#10 delayed loading groups compared to the immediate loading or immobilized specimens at 2 and 4 weeks (p<0.01). Conversely, ED2+ resident macrophages were seen in significantly higher quantities at the tendonbone interface in the delayed loading groups compared to immediately loaded or immobilized knees at both 2 and 4 weeks (p<0.02). Tartrate-resistant acid phosphatase and smooth muscle actin staining also revealed significantly less osteoclasts (p<0.01) and reduced interface tissue vascularity (p<0.003) in the delayed loading groups compared to immediate loading or immobilized specimens at 2 and 4 weeks postoperatively.
Discussion
The delayed application of cyclic axial load after ACL reconstruction results in improved mechanical and biological parameters of tendon-bone healing compared to immediate loading or prolonged postoperative immobilization of the knee. A more mature tendon-bone interface is achieved, as demonstrated by significantly increased load-to-failure, new bone formation, resident ED2+ macrophages, and reduced interface scar tissue, catabolic ED1+ macrophages, osteoclasts, and vascularity of the interface tissue. While the etiology of these differences may be multifactorial, controlled mechanical loads may be most favorable to the healing enthesis after resolution of the acute, postoperative inflammatory reaction. These findings may have critical implications for postoperative rehabilitation following ligament reconstruction. Ongoing studies using this system will provide further insight into the effect of variable magnitudes of axial load on the healing interface after ACL reconstruction.
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